

Figure S1 Knockdown of *DUOX2* inhibits the growth and invasiveness of pancreatic cancer cells *in vitro*. (A) Cell viability was detected 48 h after transfection by CCK-8 assay. (B) Cell invasiveness was detected 48 h after transfection by transwell assay. Cells were stained with 0.1% crystal violet and photographed by light microscopy (400-fold). *P<0.05; **P<0.01. DOUX2, dual oxidase 2; CCK-8, Cell Counting Kit-8; siRNA, small interfering RNA.

Table S1 Multivariable	Cox regression anal	vsis of OS in	pancreatic cancer	patients in the TCGA dataset
	0		1	

Characteristics $TCCA(n-171)$	Multivariable analysis			
Characteristics, TCGA (II=171)	HR	HR 95% CI of HR		
DUOX2				
High/low	1.41	1.131–1.723	<0.05	
Gender				
Female/male	1.270	0.669–2.410	0.465	
Age (years)				
≥65/<65	1.436	0.739–2.792	0.286	
Tumor stage				
III + IV/I + II	0.931	0.115-7.502	0.946	
Tumor grade				
III + IV/I + II	1.587	0.797–3.159	0.189	

OS, overall survival; TCGA, The Cancer Genome Atlas; HR, hazard ratio; CI, confidence interval; DOUX2, dual oxidase 2.

	Multivariable analysis			
Characteristics, TCGA (n=132)	HR 95% CI of HR		P value	
DUOX2				
High/low	1.39	1.231–1.896	<0.05	
Gender				
Female/male	1.354	0.561-2.312	0.414	
Age (years)				
≥65/<65	1.526	0.639–2.899	0.316	
Tumor stage				
III + IV/I + II	0.998	0.279–7.152	0.877	
Tumor grade				
III + IV/I + II	1.873	0.587–3.636	0.211	

Table S2 Multivariable Cox regression analysis of RFS in pancreatic cancer patients in the TCGA dataset

RFS, relapse-free survival; TCGA, The Cancer Genome Atlas; HR, hazard ratio; CI, confidence interval; DOUX2, dual oxidase 2.

Table S3 Clinicopathologic features of 44 pancreatic cancer patients

Voriablea	All cases —	DUOX2 ex	Dychuo	
Valiables		Low expression	High expression	r value
Age (years)				0.348
≥60	16	5	11	
<60	28	10	18	
Gender				0.827
Male	29	14	15	
Female	15	5	10	
Histologic grade				
Good/moderate	34	14	20	0.23
Poor	10	2	8	
Clinical stage				
I–II	34	25	9	<0.05
III–IV	10	2	8	

DOUX2, dual oxidase 2.